The expression of endothelin converting enzyme 2 and lymphocyte antigen 9 in non-small cell lung cancer tissue and clinical prognosis
Zhang Lianwei
Li Ping
Liu Yuhua
Guo Kefeng
Li Yan
Abstract：Objective To investigate the expression levels of endothelin-converting enzyme 2(ECE2)and lymphocyte antigen 9(LY9)in tissues of non-small cell lung cancer(NSCLC)patients,and to analyze their relationship with clinicopathological factors and prognosis.Methods A retrospective study was conducted on 96 NSCLC patients treated in our hospital from January 2020 to January 2022.Quantitative PCR was used to analyze the differential expression of ECE2 mRNA and LY9 mRNA in NSCLC tissues.Immunohistochemistry was performed to detect ECE2 and LY9 protein expression levels.Kaplan-Meier curves were used to analyze the impact of ECE2 and LY9 expression on NSCLC patient prognosis.Cox regres-sion analysis was used to identify prognostic factors in NSCLC patients.Results The expression levels of ECE2 mRNA(3.01±0.54 vs.0.76±0.20)and LY9 mRNA(2.76±0.46 vs.0.68±0.19)in NSCLC cancer tissues were significantly higher than those in normal lung tissues(t=38.283,40.948,both P＜0.001).The positive rates of ECE2 and LY9 in NSCLC cancer tissues were 70.83％(68/96)and 66.67％(64/96),respectively,significantly higher than those in adjacent tissues(7.29％(7/96)and 6.25％(6/96),respectively)(x2=81.417,75.631,both P＜0.001).The positivity rates of ECE2 and LY9 in NSCLC cancer tissues were significantly increased in patients with TNM stage ⅢA and lymph node metastasis(x2=13.366,5.042,15.247,6.750;P=0.000,0.025,0.006,0.009).The 3-year overall survival rate in the ECE2-positive group was 45.59％(31/68),significantly lower than the 85.71％(24/28)in the negative group(Log-rank x2/P=12.900/＜0.001).The 3-year overall survival rate in the LY9-positive group was 45.31％(29/64),significantly lower than the 81.25％(26/32)in the negative group(Log-rank x2/P=12.670/＜0.001).TNM stage ⅢA,lymph node metastasis,positive ECE2 expression,and positive LY9 expression were identi-fied as risk factors affecting NSCLC prognosis[OR(95％CI)=1.292(1.035-1.612),1.289(1.047-1.587),1.327(1.104-1.596),1.415(1.094-1.829)].Conclusion The expression of ECE2 and LY9 is elevated in NSCLC tissues and serves as no-vel biomarkers for evaluating the prognosis of NSCLC patients.
Keywords：Non-small cell lung cancerEndothelin converting enzyme 2Lymphocyte antigen 9Prognosis
Publication Date：2025-10-18
Online Publishing Date：2025-11-10(First online date of this platform, not the publication date of the document)
Pages：5( 1178-1182 )